Table 6 Haematologic toxicity

From: A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

  

Arm B

Arm C

Arm D

Toxicity type

Arm A

%Patients/%Cycles

 

Leukocytopenia

 All grades

73/70a

68/53a

70/56a

30/24b

 Grade 3–4

20/15b

14/6

15/6b

5/3b

Neutropenia

    

 All grades

73a/65b

61a/50

65a/57b

23a/15b

 Grade 3–4

34/21

25/12

28/20

9/5

 Febrile neutropenia/neutropenic infection

75

5/2

7/1

—

 

2/1

—

2/1

2/1

Anaemia

 All grades

98/92

92/87

91/90

91/83

 Grade 3–4

2/1

3/1

4/4

0/0

Thrombocytopenia

 All grades

24c/14

11c/6

15c/6

9c/8

 Grade 3–4

0/0

0/0

0/0

5/3

  1. Percentage of patients developing toxicity in all courses/percentage of cycles in which toxicity developed; worst grade during study. Number of patients is 41 in arm A, 37 in arm B, 46 in arm C and 44 in arm D; number of cycles is 127 in arm A, 98 in arm B, 130 in arm C and 76 in arm D.
  2. aArm D is significantly different from arms A, B and C (P⩽0.004).
  3. bArm D is significantly different from arms A and C (P⩽0.004).
  4. cArm A is significantly different from arms B, C and D (P⩽0.001).
Back to article page